Our experience sets us apart. We can produce more complicated products through our expertise and strategic partnerships.
Strategy Components
-
Our generic research and development strategy is focused on identifying opportunities further up the pharmaceutical value chain in Specialty Generic products, where competition is more limited and the barriers to entry are steeper.
These barriers can include advanced formulation or manufacturing technologies, more demanding product handling requirements, complex regulatory hurdles or intellectual property barriers.
-
In addition to providing greater challenges to bring to market, Specialty Generics offer a value-added component by providing treatments to patients through the use of specialized technology platforms, such as transdermal patches, liquid formulations, extended release systems or other high-tech delivery features. These technologies can offer distinct benefits to both patients and society.
Through fewer side effects and greater convenience, specialty pharmaceuticals can promote improved patient compliance to treatment regimens.
Research & Development Strategy
Alvogen is charting its course for success through a focus on licensing, developing, producing and marketing complex, high value specialty and generic drugs. As generics companies face increasing pressure on price, market share and profitability in an environment that has become highly competitive, commoditized and consolidated, Alvogen has chosen a strategy that provides differentiation and sustainability. Our R&D pipeline consists of a strong product focus; controlled release technology and transdermal drug delivery.
Alvogen is engaging in partnerships with companies that need financial, technical and/or regulatory support to bring their specialty product candidates to market. Our seasoned team can provide the market guidance, formulation optimization, process optimization, regulatory strategy and manufacturing support necessary to bring about regulatory submission. Further, we continue to see multiple product acquisition opportunities in the market resulting from continued pharmaceutical consolidation and M&A activity.
